PSTV - Bathi operasional EBITDA plustherapeutics.com

Plus Therapeutics, Inc. (PSTV) maintains capital stability through government grants for radiopharmaceutical development, which reduces costs. Revenues are based on insurance reimbursements for high-tech tumor irradiation. However, the lack of revenue during the testing phase of CNS drugs increases unit costs. The EBITDA financial metric clearly demonstrates the current trend, where the value settled at 0.00.

For Plus Therapeutics, Inc. (PSTV), which holds unique radiotherapy patents within the FDA's stringent regulatory framework, this metric serves as an indicator of the operating cycle's actual liquidity. An analysis of EBITDA allows for an assessment of net cash flow excluding non-cash charges, which is critical for evaluating the company's resilience to clinical trial costs and preventing capital freezes.